Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M; PEACE Consortium; Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; TRACERx Renal Consortium. Au L, et al. Among authors: lund t. Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28. Cancer Cell. 2021. PMID: 34715028 Free PMC article.
Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.
Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC. Serrels A, et al. Among authors: lund t. Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001. Cell. 2015. PMID: 26406376 Free PMC article.
Neoantigen-directed immune escape in lung cancer evolution.
Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C; TRACERx consortium. Rosenthal R, et al. Among authors: lund t. Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20. Nature. 2019. PMID: 30894752 Free PMC article.
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R, Al Bakir M, Zapata L, Hiley CT, Officer L, Sereno M, Smith CR, Loi S, Hackshaw A, Marafioti T, Quezada SA, McGranahan N, Le Quesne J; TRACERx Consortium; Swanton C, Yuan Y. AbdulJabbar K, et al. Among authors: lund t. Nat Med. 2020 Jul;26(7):1054-1062. doi: 10.1038/s41591-020-0900-x. Epub 2020 May 27. Nat Med. 2020. PMID: 32461698 Free PMC article.
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca AU, Rosenthal R, Kalinke L, Chandrasekharan DP, Pipinikas CP, Lee-Six H, Hynds RE, Gowers KHC, Henry JY, Millar FR, Hagos YB, Denais C, Falzon M, Moore DA, Antoniou S, Durrenberger PF, Furness AJ, Carroll B, Marceaux C, Asselin-Labat ML, Larson W, Betts C, Coussens LM, Thakrar RM, George J, Swanton C, Thirlwell C, Campbell PJ, Marafioti T, Yuan Y, Quezada SA, McGranahan N, Janes SM. Pennycuick A, et al. Among authors: lund t. Cancer Discov. 2020 Oct;10(10):1489-1499. doi: 10.1158/2159-8290.CD-19-1366. Epub 2020 Jul 20. Cancer Discov. 2020. PMID: 32690541 Free PMC article.
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Ghorani E, Reading JL, Henry JY, Massy MR, Rosenthal R, Turati V, Joshi K, Furness AJS, Ben Aissa A, Saini SK, Ramskov S, Georgiou A, Sunderland MW, Wong YNS, Mucha MV, Day W, Galvez-Cancino F, Becker PD, Uddin I, Oakes T, Ismail M, Ronel T, Woolston A, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Litchfield K, Conde L, Guerra-Assunção JA, Blighe K, Biswas D, Salgado R, Lund T, Bakir MA, Moore DA, Hiley CT, Loi S, Sun Y, Yuan Y, AbdulJabbar K, Turajilic S, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Chain B; TRACERx Consortium; Swanton C, Quezada SA. Ghorani E, et al. Among authors: lund t. Nat Cancer. 2020 May;1(5):546-561. doi: 10.1038/s43018-020-0066-y. Epub 2020 May 22. Nat Cancer. 2020. PMID: 32803172 Free PMC article.
Genetic and immune landscape evolution in MMR-deficient colorectal cancer.
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R, Assiotis I, Fenwick K, Begum R, Begum D, Lund T, Sivamanoharan N, Sansano HB, Domingo-Arada M, Tran A, Pandha H, Church D, Eccles B, Ellis R, Falk S, Hill M, Krell D, Murugaesu N, Nolan L, Potter V, Saunders M, Shiu KK, Guettler S, Alexander JL, Lázare-Iglesias H, Kinross J, Murphy J, von Loga K, Cunningham D, Chau I, Starling N, Ruiz-Bañobre J, Dhillon T, Gerlinger M. Challoner BR, et al. Among authors: lund t. J Pathol. 2024 Feb;262(2):226-239. doi: 10.1002/path.6228. Epub 2023 Nov 15. J Pathol. 2024. PMID: 37964706
Longitudinal assessment of tumor-infiltrating lymphocytes in primary breast cancer following neoadjuvant radiotherapy.
Yoneyama M, Zormpas-Petridis K, Robinson R, Sobhani F, Provenzano E, Steel H, Lightowlers S, Towns C, Castillo SP, Anbalagan S, Lund T, Wennerberg E, Melcher A, Coles CE, Roxanis I, Yuan Y, Somaiah N. Yoneyama M, et al. Among authors: lund t. Int J Radiat Oncol Biol Phys. 2024 Apr 26:S0360-3016(24)00566-2. doi: 10.1016/j.ijrobp.2024.04.065. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38677525
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Lund T, Gundesen MT, Juul Vangsted A, Helleberg C, Haukås E, Silkjær T, Asmussen JT, Manuela Teodorescu E, Amdi Jensen B, Schmidt Slørdahl T, Nahi H, Waage A, Abildgaard N, Schjesvold F; Nordic Myeloma Study Group. Lund T, et al. Blood Cancer J. 2024 Apr 15;14(1):65. doi: 10.1038/s41408-024-01046-2. Blood Cancer J. 2024. PMID: 38622134 Free PMC article. No abstract available.
835 results